HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure

HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure

Hageman factor (FXII) is an essential component in the intrinsic coagulation cascade and a therapeutic target for the prophylactic treatment of hereditary angioedema (HAE). CSL312 (garadacimab) is a novel high-affinity human antibody capable of blocking activated FXII activity that is currently unde...

Full description

Saved in:
Bibliographic Details
Main Authors: Saw Yen Ow, Eugene A. Kapp, Vesna Tomasetig, Anton Zalewski, Jason Simmonds, Con Panousis, Michael J. Wilson, Andrew D. Nash, Matthias Pelzing
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:mAbs
Subjects:
HDX-MS
binding stoichiometry
epitope mapping
Hageman factor
negative stain electron microscopy
SPR
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2022.2163459
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2022.2163459

Similar Items